75 results about "Esophagitis" patented technology

An application of the montmorillonite nanoparticles in preparing the medicine for treating the ulcer in digestive tract, regurgitation of stomach and esophagus, esophagitis, gastritis, colitis, acute diarrhea, chronic atrophic gastritis is disclosed. Its composite medicine is also disclosed.

The invention relates to the technical field of antibodies, and especially relates to a human thymus stromal lymphopoietin monoclonal antibody and an application thereof. The TSLP antibody can be specifically combined with hTSLP, has high affinity, and can effectively inhibit the combination of TSLP and a receptor thereof so as to inhibit activation of a downstream signal path and activation of immune cells by TSLP. The TSLP antibody has great significance in detection of the content of hTSLP and allergic asthma, and diagnosis, treatment and prognosis of inflammatory or allergic inflammatory diseases such as chronic obstructive pulmonary disease, allergic dermatitis, allergic rhinitis, allergic nasosinusitis, eosinophilic granulocytic esophagitis, allergic conjunctivitis, inflammatory bowel disease or atopic dermatitis.

Provided is a hyaluronic acid (HA) composition for use in treating or preventing mucosa related disorders or diseases including a mixture of HAs having different average molecular weights and different rheological, isolation, tissue scaffold and degradation properties. The resulting formulation demonstrates an optimal balance between adhesion, tissue scaffold and treating time on the treatment and prevention of mucosa related disorders or diseases including conjunctivitis, otitis, allergic rhinitis, gingivitis, oral ulcer, bronchitis, gastroesophageal reflux disease (GERD), esophagitis, gastritis, enteritis, peptic ulcer, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), urethritis, cystitis and vaginitis.

Provided by the present invention are methods of treating a variety of disorders including AIDS, arthritis (rheumatoid arthritis, osteoarthritis, spondyloarthropathies), antibiotic induced diarrheal diseases (Closbidium difficile), multiple sclerosis, osteoporosis, gingivitis, peptic ulcer disease, esophagitis, diabetes, retinitis, uveitis, reperfusion injury after myocardial infarction (MI) or cerebral vascular accident (CVA), aphthous ulcers (oral), atherosclerosis (plaque rupture), prevention of tumor metastases, asthma, preeclampsia, acute pancreatitis, psoriasis, infertility and allergic disorders such as rhinitis, conjunctivitis, and urticaria.

The present invention relates to novel biologically active glutarimide derivatives of general formula (I) or a pharmaceutically acceptable salt thereof, their use as a therapeutic agent for the treatment of eosinophilic diseases, preferably of allergic nature, in particular bronchial asthma, allergic rhinitis, polypous rhinosinusopathies, eosinophilic colitis, eosinophilic syndrome, allergic conjunctivitis, atopic dermatitis, Churg-Strauss syndrome, anaphylactic shock, Quincke's edema, eosinophilic vasculitis, eosinophylic esophagitis, eosinophilic gastroenteritis, or fibroses. The invention also relates to pharmaceutical compositions comprising glutarimide derivatives of general formula (I):

A method for treatment of esophagitis is disclosed in which a therapeutic composition is introduced into the esophagus to contact a mucosal surface within the esophagus. The pharmaceutical composition comprises a reverse-thermal gelation polyoxyalkylene block copolymer, a pharmaceutical substance and a pharmaceutical substance selected from the group consisting of glutathione and a precursor for glutathione biosynthesis.

The invention discloses a medicament for treating esophagitis, which is prepared from platycodon root, liquorice, scutellaria, dried orange peel, pericarpium trichosanthis, longstamen onion bulb, honeysuckle, rhizoma corydalis and frank incense serving as raw materials. The medicament can be prepared into a plurality of preparations for clinical use; and components in the medicament are coordinated, a theory of diagnosis and treatment based on an overall analysis of the illness and the patient's condition is used, so that the medicament has the advantages of excellent effect on diseases, such as the esophagitis and the like, no toxic or side effect, and safe and reliable clinical use.

Provided by the present invention are topical formulations of Interleukin-11 and methods for treating a variety of disorders, including inflammatory bowel diseases (e.g., Crohn's disease, ulcerative colitis, indeterminate colitis, and infectious colitis), mucositis (e.g., oral mucositis, gastrointestinal mucositis, nasal mucositis, and proctitis), necrotizing enterocolitis, inflammatory skin disorders (e.g., psoriasis, atopic dermatitis, and contact hypersensitivity), aphthous ulcers, pharyngitis, esophagitis, peptic ulcers, gingivitis, periodontitis, and ocular diseases (e.g., conjunctivitis, retinitis, and uveitis).

An anti-inflammatory walnut oil is prepared from, by weight, 300-320 parts of kernel of Juglans cathayansis Dode var. formosana A. M. Lu et R. H. Chang, 50-60 parts of peanut, 50-60 parts of coix seed, 30-40 parts of laver, 20-30 parts of litchi, 50-60 parts of Rhizoma Coptidis and 10-15 parts of Fructus Evodiae. Laver and litchi are added in the preparation process, and have anti-ultraviolet, anti-oxidation and anti-ageing effects and benefit the health of body; bitter and cold Rhizoma Coptidis capable of clearing and purging liver heat is added to realize liver heat clearing and no transverse dysfunction invading stomach, Rhizoma Coptidis also can clear stomach heat, and the stomach heat lowering causes qi lowering, so simultaneous treatment of principal and subordinate symptoms is realized, and double benefits are achieved; and a small amount of the spicy, hot, dredging and benefiting Fructus Evodiae is added, and can introduce medicines to liver meridian and depress qi to assist Rhizoma Coptidis to harmonize stomach, lower the adverse flow of qi, dispel cold and sooth the liver in order to realize dissipation excessive stagnation of fire principle. The qi depressing effect of Fructus Evodiae is used to assist Rhizoma Coptidis to harmonize stomach and lower the adverse flow of qi, the Fructus Evodiae is spicy and hot, has strong stagnation removal does not assist heating, can smooth liver qi and relieve stagnation, can solve bitterness and coldness of Rhizoma Coptidis to make internal heat purging without cold constraining abuses, can clear heat and detoxify, and is suitable for being eaten by esophagitis, gastritis, gastroduodenal ulcer and other liver fire invading stomach patients.

The invention discloses a composite dyeing agent and an application thereof. The composite dyeing agent is mixed liquid consisting of an acetic acid solution, a toluidine blue solution and normal saline, wherein in the mixed liquid, the mass concentration of acetic acid is 1.5%-2%, and the mass concentration of toluidine blue is 0.2%-0.4%. The composite dyeing agent cooperates with a gastroenterological endoscope, so that the focus of a disease, which is difficult to distinguish can be convenient to find, and the composite dyeing agent is particularly used for esophagitis of dogs, and can improve the diagnosis rate and the sensibility of the esophagitis of the dogs.

The present invention discloses a kind of astringing and diarrhea relieving orally taken dispersive tablet and its preparation process. The tablet is prepared with the main material including montmorillonite and rhizome of featherleaf rodgersflower and supplementary material including filler, disintegrating agent, corrective and flow aid in certain weight proportion. The astringing and diarrhea relieving orally taken dispersive tablet is used in treating acute and chronic diarrhea, gastritis, esophagitis, colitis, GERD, etc of adult and children.

The present invention provides methods of diagnosing and identifying subjects as having GERD comprising detecting E-cadherin fragments in a biological sample from the subject. The invention further provides methods for identifying subjects as having heartburn that is responsive to proton pump inhibitor therapy and subjects having an increased likelihood of a rapid relapse of GERD after reducing the dosage of PPIs or terminating PPI therapy. In addition, the present invention provides methods for monitoring the healing of erosive and nonerosive esophagitis of GERD without the need for esophagogastroduodenoscopy or esophagogastroduodenoscopy and biopsy, respectively.

The invention provides six-in-one anti-reversion particles and a preparation method thereof. The six-in-one anti-reversion particles are prepared from the following components in parts by weight: 600gof lily, 200 g of lindera aggregata, 200g of radix aucklandiae, 300g of vinegar-processed rhizoma corydalis, 300g of rhizoma cyperi, 180g of coptis chinensis, 60g of fructus evodiae and 240g of fructus aurantii. The invention also provides the preparation of the six-in-one anti-reversion particles. The preparation method comprises the following steps: S1) adding 5 times of water into the radix linderae, the radix aucklandiae, the rhizoma cyperi and the fructus aurantii, distilling for 3 hours, receiving distillate, standing, taking out a volatile oil layer for later use, and filtering a distilled water solution to obtain filtrate and medicine residues; S2) mixing the decoction dregs, lily, vinegar processed corydalis tuber, coptis chinensis and fructus evodiae, adding 8 times of water, decocting for three times, then filtering, combining filtrates, and standing overnight; and S3) taking out the supernatant of the combined filtrate. The six-in-one anti-reversion particles have a remarkable clinical effect on liver-stomach stagnated heat type esophagitis, have no recurrence and no side effect after drug withdrawal, and are convenient to popularize and use.

The invention discloses a medicament for treating a gastrointestinal disease. The medicament comprises the following medicinal materials serving as active ingredients: 3 to 6g of cutch, 3 to 6g of gallnut, 3 to 6g of dragon's blood, 3 to 10g of costustoot, 6 to 9g of beautyberry and 1 to 3g of centipede. A composition consisting of the medicinal materials can effectively treat the gastrointestinal disease; and the medicinal materials are common medicinal materials, have low price, can be used as an oral preparation in clinical use and can be directly and orally taken in the form of powder composition or orally taken in the form of capsules. The medicament is suitable for treating esophagitis, gastric ulcer, gastric erosion, gastric perforation, gastric bleeding, gastrointestinal polyp, gastrointestinal metaplasia, gastratrophy, helicobacter pylori and gastric cancer and can help recovery after surgeries of gastric cancer and intestinal cancer.

The invention provides a traditional Chinese medicine preparation for treating peptic ulcer, gastritis and reflux esophagitis as well as a preparation method and an application thereof. The traditional Chinese medicine preparation provided by the invention is prepared by the steps of: roasting and crushing coptis chinensis, rheum officinale, pseudo-ginseng and bletilla; mixing the optis chinensis, rheum officinale, pseudo-ginseng and bletilla with Yunnan Baiyao in a weight ratio; and adding medicinal auxiliary materials in a medicinal amount. Through scientific proportioning and clinic observation, the formula provided by the invention can effectively and safely treat peptic ulcer, gastritis and esophagitis of all kinds and reflux esophagitis, and is remarkable in curative effect, low in recurrence rate and free of toxic and side effects; the action and curative effect of the preparation can be comparable to those of an anti-ulcer agent, a gastric motor drug, a gastric mucosa protective agent and an anti-helicobacter pylori western medicine. The traditional Chinese medicine preparation provided by the invention has various functions of western medicine in clinical treatment and is the most effective traditional Chinese medicine formula for treating peptic ulcer, gastritis and esophagitis, improving the clinical symptoms and radically treating ulcer and preventing relapse in traditional Chinese medicine treatment at present. A purpose of treating both causes and symptoms is achieved.

The invention provides a traditional Chinese medicine composition for treating acid reflux, which comprises the following raw materials in parts by weight: 2-15g of radix curcumae, 2-10g of cape jasmine, 2-15g of bamboo shavings, 2-10g of pseudo-ginseng, 3-12g of ginger, 10-30g of pearl shell, 3-12g of light fermented soya bean, 5-20g of cuttlebone, 3-12g of honey-fried licorice root, 5-25g of loquat leaf, 3-15g of dried tangerine peel, 5-25g of dandelion, and 5-25g of jujube. The preparation method comprises the following steps: taking the raw material medicines for cleaning and removing impurities, adding water to decoct the materials and merging filtrates, concentrating and cooling the materials, adding ethanol to make an alcohol content of 20 to 80%, recovering the ethanol, and concentrating a supernatant into a thick paste for standby; and drying the thick paste to prepare a corresponding dosage form, wherein the dosage form includes a pill, a lozenge, pulvis, a powder, a particulate agent or a decoction bag. The traditional Chinese medicine composition can cure the acid reflux, treat the esophagitis, esophageal reflux and pharyngitis caused by the acid reflux, and can restorethe elasticity of the sphincter, simultaneously purify the stomach, and regulate and consolidate the gastric mucosa.

The present invention provides methods for treating inflammatory conditions, including but not limited to, inflammatory bowel disease (ulcerative colitis, Crohn's disease, and proctitis), other noninfectious, inflammatory conditions of the GI tract (microscopic colitis, allergic eosinophilic gastroenteritis, food allergies, pill induced esophagitis, celiac disease, recurrent polyps, and hemorrhoids), and psoriasis, using progesterone or progesterone analogs such as medroxyprogesterone acetate.

The invention discloses a postoperative drug for chronic peptic ulcer and esophagitis syndrome. The drug is applied to the postoperative treatment of chronic peptic ulcer and esophagitis syndrome. The drug is characterized by being prepared from the following raw pharmaceutical materials in proportioning ratio by weight: litchi chinensis Sonn., lindernia ruellioides (Colsm.)Pennell, polygonum orientale L., radix platycodi, aeschynomene indica L., trachelospermum jasminoides (Lindl.) Lem., radix puerariae, paris polyphylla Sm., luffa cylindrica (L.) Roem., manis pentadactyla Linnaeus, hordeum vulgare L. and setaria italica (L.) Beauv.. Proved by clinical trials, the drug has the characteristics of low recurrence rate and high safety in the postoperative treatment of chronic peptic ulcer and esophagitis syndrome, so that the method is worthy of clinical application and popularization.